Pharmaceutical organisations operate across borders, sell to governments, and rely on complex distributor networks. The operating model is familiar. The intensity of regulatory scrutiny is not. Commercial pressure, employee fraud, online scams and a greater willingness to speak up are increasing the likelihood that leaders will need to respond to serious allegations at speed.
For boards and executive teams, investigation readiness is a governance capability, not simply a compliance process. It means being able to assess an allegation quickly, preserve confidential evidence, mobilise the right expertise and reach defensible decisions without alerting those involved or allowing evidence to disappear.
Why the risk profile remains high
With Pharmaceutical companies operating globally across multiple markets, they often sell their products and services, directly or indirectly to government customers. This exposure can increase anti-bribery and corruption risk, particularly where third parties operate in higher-risk jurisdictions. Commercial targets and bonus structures can also create incentives for misconduct, while employee fraud, scams and cyber threats continue to evolve.
“The risk is not new, but the expectation that organisations can identify, investigate and respond to it is higher than ever.” - Nigel Layton – Partner - Global Head of Life Sciences/Pharma
The consequences can be significant. Anti-bribery breaches can lead to substantial penalties and lasting reputational damage. For senior leaders, exposure extends beyond legal risk. It can affect market access, stakeholder confidence and the organisation’s ability to show that it controls work in practice.
Whistleblowing has changed the starting point
Whistleblowing channels are now central to the control environment in major organisations. By enabling people to raise concerns, including anonymously, they can bring hidden issues to light. Receiving a complaint, however, is only the beginning.
Organisations need a clear process to assess whistleblower complaints and direct them to the right response, whether the concern involves fraud, regulatory compliance or bribery and corruption. This first assessment should determine ownership, urgency, confidentiality and whether specialist external support is needed.
Confidentiality is critical. Unplanned interviews or early signals that devices will be collected can alert those involved. Evidence may then be deleted, altered or concealed. Early expert input helps protect the integrity of the investigation before formal steps begin.
Sector knowledge and cross-border capability matter
Pharmaceutical investigations can involve large, technically complex data sets, particularly in clinical trials, research and development and other regulated activities. Investigators need analytical capability and sector knowledge to identify what matters and understand its significance.
Global operations add complexity. Cross-border investigations must account for local laws, particularly those governing data privacy, evidence collection and employment. An approach that works in one jurisdiction cannot simply be applied in another.
“In a global pharmaceutical investigation, technical expertise is only part of the answer. You also need sector specialists and people who understand the local legal and data environment.” - Nigel Layton – Partner - Global Head of Life Sciences/Pharma
C-suite leaders should select an investigation team for both subject-matter expertise and geographic reach. A credible response combines investigative experience, pharmaceutical sector knowledge and an understanding of every relevant jurisdiction.
Secure the evidence before analysing it
The first operational priority is evidence preservation. Relevant computers, emails, messaging data and other sources should be identified, imaged and secured. Investigators can then follow leads, conduct background research and prepare for interviews from a reliable evidence base.
“AI can help analyse evidence, but it does not remove the need to secure that evidence properly or to test the findings with experienced human judgement.” - Nigel Layton – Partner - Global Head of Life Sciences/Pharma
Artificial intelligence (AI) can accelerate review and help investigators work through large volumes of information. It is not a substitute for sound evidence collection or experienced judgement. A balanced approach combines technology with established investigative methods and tests whether all reasonable lines of enquiry have been covered.
What investigation readiness looks like in practice
Effective investigation readiness starts with procedures that are easy to follow when a complaint arrives. The process should explain how allegations are triaged, who decides the response and when responsibility sits with internal audit, risk, finance or an external investigation team.
It should also define how evidence will be gathered and protected, who is qualified to conduct research and interviews and how cross-border legal requirements will be managed. The aim is not to prescribe every step. It is to remove avoidable uncertainty when speed, confidentiality and judgement matter most.
Five priorities for boards and executive teams:
- Review the compliance framework. Test whether pharmaceutical compliance systems address relevant anti-bribery requirements, including risk assessment and due diligence on suppliers and distributors.
- Strengthen triage. Give the team responsible for whistleblower complaints clear criteria for severity, confidentiality, ownership and escalation.
- Know when to call specialists. Set thresholds for involving external investigators before internal activity risks alerting subjects or compromising evidence.
- Map evidence and jurisdictions. Confirm where critical information is held, how it can be secured and which local privacy or employment rules apply.
- Focus on third-party risk. Ensure distributors and other intermediaries are briefed, trained, checked and audited because their conduct can create direct exposure for the organisation.
Preparedness gives leaders control
No organisation can prevent every allegation. It can decide whether the response begins with confusion or a tested process. Boards should review the compliance framework, confirm how whistleblower allegations will be triaged, ensure evidence can be secured quickly and identify the internal and external specialists they may need.
“Investigation readiness means having clear procedures, experienced people and a plan for securing evidence before the pressure of a live case begins." - Nigel Layton – Partner - Global Head of Life Sciences/Pharma
The strongest position is to act before an issue arises. Robust procedures, proportionate due diligence and clear investigation protocols will not remove the need to investigate. They will, however, provide a stronger foundation for regulatory engagement, remediation and the protection of long-term trust.
| |
To speak to our pharma and life sciences experts. Get in touch |
